Welcome
Antitrust

Amgen, Teva Ordered to Face Generic Delay Claims Over Sensipar

Nov. 30, 2020, 6:48 PM

Amgen Inc. and Teva Pharmaceuticals Industries Ltd. must face a lawsuit claiming Amgen offered Teva a “reverse payment” when it settled patent litigation over its calcium reducer Sensipar in exchange for Teva’s pledge to pull its generic version and pay suspiciously low damages, a Delaware federal judge ruled Monday.

Teva’s $40 million payment “cannot be divorced from what Teva did not pay,” Judge Leonard P. Stark wrote. By dropping the patent case, “Amgen was permitting Teva to retain at least some of the” nearly $400 million it “earned at Amgen’s expense” during the one-week “at risk” launch of its Sensipar...

To read the full article log in.